Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.62 |
| ▸ | SYK | P43405 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 2/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005802 | 0.83 | SYK (0.63) | OPRM1OPRK1OPRD1SYK | |
| SCHEMBL17005759 | 0.81 | SYK (0.55) | SYK | |
| SCHEMBL3694156 | 0.77 | OPRM1 (1.00) | OPRM1OPRK1OPRD1ABCB1 | |
| SCHEMBL18351928 | 0.76 | SYK (1.00) | SYK | |
| SCHEMBL18351929 | 0.76 | SYK (1.00) | SYK | |
| SCHEMBL17005763 | 0.76 | SYK (0.63) | SYK | |
| SCHEMBL18351855 | 0.76 | SYK (0.63) | SYK | |
| SCHEMBL17005748 | 0.75 | SYK (0.61) | SYKKMT2A | |
| SCHEMBL17005803 | 0.74 | SYK (0.63) | SYKSMN1; SMN2 | |
| SCHEMBL17005751 | 0.74 | SYK (0.64) | SYKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533989-B2 | Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors | Ziarco Pharma Ltd. (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20150232470-A1 | 2-(-Aminocyclohexyl)Amino-Pyrimidine-5-Carboxamides as Spleen Tyrosine Kinasei(SYK) Inhibitors | PFIZER LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232470-A1 | 2-(-Aminocyclohexyl)Amino-Pyrimidine-5-Carboxamides as Spleen Tyrosine Kinasei(SYK) Inhibitors | SYK, BTK, LCK | OPRM1 3934/4885OPRK1 2013/4885OPRD1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.